Aditxt, Inc. Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount
Aditxt, Inc. (ADTX) had Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount of $1.67 million as of 2020-12-31, per its 10-K filed 2022-03-31.
Discontinued › Balance Sheet › Liabilities
us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmount · last filed 2022-03-31
- 2020-12-31: Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount $1.67M.
| Period end | Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount |
|---|---|
| 2020-12-31 | $1.67M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |